Understand the source comparison
Best Peptides for Low IGF-1 Levels: Mechanism Comparison
CJC-1295 with DAC GHRH analogue. Stimulates pituitary GH synthesis and release, extended half-life 38–50% (monotherapy) Once or twice weekly (subcutaneous) Requires combination with GHRP for optimal effect Most reliable long-term option when paired with ipamor
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 with DAC
- GHRH analogue. Stimulates pituitary GH synthesis and release, extended half-life
- 38–50% (monotherapy)
- Once or twice weekly (subcutaneous)
- Requires combination with GHRP for optimal effect
- Most reliable long-term option when paired with ipamorelin
- CJC-1295/Ipamorelin
- Synergistic GHRH + GHRP action. Amplifies GH pulses, suppresses somatostatin
- 70–90%
- Daily or twice-daily (subcutaneous)
- Requires consistent dosing schedule
- Gold standard combination for sustained IGF-1 elevation
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist. Mimics ghrelin, 24-hour half-life
- 80–100%
- Once daily (oral)
- Increases appetite, mild insulin resistance in some users
- Best option for those unable or unwilling to inject
- Hexarelin
- High-potency GHRP. Strongest GHS-R1a activation
- 100–120%
- 2–3 times daily (subcutaneous)
- Stimulates cortisol/prolactin, faster receptor desensitisation
- Most potent short-term option, not ideal for protocols beyond 12 weeks
- GHRP-2
- Moderate-potency GHRP. Balanced GH release with minimal cortisol elevation
- 50–70%
- Less potent than hexarelin, more frequent dosing than CJC-1295 with DAC
- Middle-ground option between ipamorelin and hexarelin